ABSTRACT

Introduction: Perception of illness varies among individuals and psoriasis of the same severity can be perceived in different ways by patients, making it essential to evaluate quality of life (QoL) since it can provide information on the impact of the disease on the patient’s overall well-being. The use of patient-reported outcomes in clinical trials provides the ability to integrate objective clinical assessment with the patient’s perception of their own state of health.

Areas covered: The introduction of anti-IL17 agents in clinical practice has given patients the possibility to achieve a PASI90 response (almost clear skin) or even higher (complete clear skin) in the majority of patients. There is accumulating evidence in support of PASI90 response as the new standard goal for therapy based on its greater correlation with health-related QoL. The present review summarizes current knowledge of the effects of secukinumab on the QoL of patients with psoriasis using patient-reported outcome measures.

Expert Opinion: Secukinumab, the first approved drug of this new class, has fully reached a new therapeutic paradigm not only in terms of clinical efficacy, but also in terms of patient satisfaction and self-rated health.

摘要

简介: 个体对疾病的看法不同，患者对相同严重程度的银屑病有不同的看法，因此评估生活质量 (QoL) 至关重要，因为它可以提供有关疾病对患者整体健康影响的信息-存在。在临床试验中使用患者报告的结果提供了将客观临床评估与患者对其自身健康状况的看法相结合的能力。

涵盖的领域：在临床实践中引入抗 IL17 药物使患者有可能在大多数患者中实现 PASI90 反应（几乎透明的皮肤）甚至更高的反应（完全透明的皮肤）。有越来越多的证据支持 PASI90 反应作为新的标准治疗目标，因为它与健康相关的生活质量有更大的相关性。本综述使用患者报告的结果指标总结了目前关于苏金单抗对银屑病患者生活质量影响的知识。

专家观点：该类新药首个获批的苏金单抗不仅在临床疗效方面，而且在患者满意度和自评健康方面，全面达到了新的治疗范式。